Fig. 3From: Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysisRisk of HBVr between HCC patients and non-HCC patients. HBVr hepatitis B virus reactivation, HCC hepatocellular carcinoma, ES effect size, CI confidence intervalBack to article page